Form 4: Danaher Corp Executive Gutierrez-Ramos Reports Stock and Option Grants

Jose-Carlos Gutierrez-Ramos, SVP and Chief Science Officer of Danaher Corp, reports the acquisition of restricted stock units and employee stock options.

Summary

• On March 1, 2024, Jose-Carlos Gutierrez-Ramos, SVP, Chief Science Officer of Danaher Corp, reported transactions involving Danaher Corp's common stock and derivative securities.
• Gutierrez-Ramos acquired 2,932 restricted stock units (RSUs) payable solely in common stock.
• One fourth of the RSUs vest on each of the first four anniversaries of the grant date, which is March 1, 2024.
• He also acquired 16,285 employee stock options with an exercise price of $255.87, where one half of the options granted become exercisable on each of the third and fourth anniversaries of the grant date, which is March 1, 2024.
• Additionally, he acquired 6,979 employee stock options with an exercise price of $255.87, where one fourth of the options granted become exercisable on each of the first four anniversaries of the grant date, which is March 1, 2024.
• Following these transactions, Gutierrez-Ramos beneficially owns 12,958 shares of common stock, 16,285 employee stock options, and 6,979 employee stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grants align executive interests with shareholders, but it's a routine disclosure.

Positives

• The grant of RSUs and stock options to a key executive like Gutierrez-Ramos aligns his interests with those of the shareholders.
• The vesting schedules encourage long-term commitment and performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the compensation structure and equity ownership of key executives.

Comparison to Industry Standards

• Stock option and RSU grants are a standard component of executive compensation packages in large corporations like Danaher.
• Companies like Siemens, Roche, and Thermo Fisher Scientific also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules are typical for such grants, aligning executive interests with long-term shareholder value.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term performance.
• Employees may see the grants as part of a competitive compensation package.

Key Dates